DOCSLIB.ORG

I EFFECTS of CHRONIC METHYLPHENIDATE ON

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
I EFFECTS of CHRONIC METHYLPHENIDATE ON EFFECTS OF CHRONIC METHYLPHENIDATE ON DOPAMINE/SEROTONIN INTERACTIONS IN THE MESOLIMBIC DA SYSTEM OF THE MOUSE BY BETHANY R. BROOKSHIRE A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Physiology and Pharmacology May 2010 Winston-Salem, North Carolina Approved by: Sara R. Jones, Ph.D., Advisor ___________________________________ Examining Committee: Dwayne W. Godwin, Ph.D., Chairman ____________________________________ David C. S. Roberts, Ph.D. ____________________________________ Brian McCool, Ph.D. ____________________________________ Jeff L. Weiner, Ph.D. ____________________________________ Paul W. Czoty, Ph.D. ____________________________________ i ACKNOWLEDGEMENTS Firstly, I would like to express my gratitude to my advisor, Sara R. Jones, PhD. Working in her lab has been both a wonderful educational experience as well as a pleasure. She had always offered guidance, support, and numerous professional opportunities. I am proud to have been trained in her laboratory. I would also like to acknowledge the excellent guidance of my committee: Drs. Godwin, Roberts, McCool, Weiner, and Czoty. They have never hesitated to offer mentorship and advice, and have been instrumental in the development of my work. Additionally, I would like to express my gratitude to Dr. Mary Lou Voytko, who has never hesitated to give me sound advice and mentorship. I would like to thank the members of the Jones Lab, past and present. Drs. Tiffany Mathews and Yolanda Mateo for their fantastic support and training, Drs Rodrigo Espana and Mark Ferris, for their fantastic professional guidance, and Joanne Konstantopolous and Jason Locke, for their constant technical assistance and support. I would also like to acknowledge Dr Kim Huggins, Dr. Erik Oleson, Jordan Yorgason, Erin Calipari, and James Melchior, they have always helped to make the lab an enjoyable experience. I would like to acknowledge the support of the Department of Physiology and Pharmacology and the Neuroscience Program. Their members have always been a willing source of advice. Special thanks to Stephanie Williard, Dr. Keri Chiodo, Dr. Anushka Goonadwardena, Tamara Spence, Dr. John Burkhardt, Kimberly Bernosky, and Dr. Greg Tinkler for their unwavering support and friendship. ii I cannot express enough thanks to my family and friends. My father, Dr. Bob Brookshire, my mother, Cathy Brookshire, and my brother, David Brookshire, who have been endlessly supportive and caring, and never stop making me laugh. I also want to recognize Mr. Vincent Piattelli, who is always a source of caring, support, sound advice, and perspective. My friends both in Winston Salem and everywhere else, who are always there to help motivate me when I need it, and who have helped to shape me into who I am, personally and professionally. I would particularly like to recognize Dr. Paul Heideman, my undergraduate mentor, who always encouraged me scholastically, and whose excellent lectures in Animal Physiology put me on the path toward graduate school. iii TABLE OF CONTENTS Page LIST OF ABBREVIATIONS…………………………………………..…………… vi LIST OF TABLES AND FIGURES ……………………….………………………. ix ABSTRACT …………………………………………………………………………. xiv Chapter I. INTRODUCTION. SECTION I: EFFECTS OF ACUTE AND CHRONIC METHYLPHENIDATE ON THE NEUROBIOLOGY AND BEHAVIOR OF RATS …………………………………………. 1 SECTION II: EFFECTS OF SPECIFIC 5-HT RECEPTOR SUBTYPES ON ACTIVATION OF DOPAMINE SIGNALING AND PSYCHOSTIMULANT RESPONSES IN THE VENTRAL TEGMENTAL AREA/NUCLEUS ACCUMBENS 47 PATHWAY……………………………………………………… II. CHRONIC METHYLPHENIDATE TREATMENT REVERSES NEGATIVE SEROTONIN EFFECTS OF DRUG REWARD: A ROLE FOR 5-HT1B RECEPTORS …………………………….. 116 Submitted to Neuropsychopharmacology, January, 2010. III. SENSITIZATION OF 5-HT1A and 1B RECEPTORS IN THE VENTRAL TEGMENTAL AREA FOLLOWING TREATMENT WITH CHRONIC METHYLPHENIDATE ……. 155 In preparation for submission to Neuropsychopharmacology, May, 2010. IV. CHRONIC MPH ADMINISTRATION IN MICE PRODUCES DEPRESSIVE-LIKE EFFECTS AND ALTERED BEHAVIORAL RESPONSES TO ANTIDEPRESSANTS …… 200 In preparation for submission to Pharmacology, Biochemistry, and Behavior, March, 2010. iv V. TEMPORARY EFFECTS OF CHRONIC MPH ON DA/5-HT INTERACTIONS IN MICE: EVIDENCE FOR 5-HT INVOLVEMENT IN EARLY BEHAVIORAL SENSITIZATION ……………………………………………….. 229 In preparation for submission to Psychopharmacology, March, 2010. VI. DIRECT AND INDIRECT 5-HT RECEPTOR AGONISTS PRODUCE GENDER-SPECIFIC EFFECTS ON LOCOMOTOR AND VERTICAL ACTIVITY IN C57 BL/6J MICE ……………………………………………………………. 259 Published in Pharmacology, Biochemistry, and Behavior, August, 2009. VII. SUMMARY AND DISCUSSION ……………………………… 323 VIII. SCHOLASTIC VITA …………………………………………… 348 IX. APPENDIX I: ETHANOL-INDUCED HYPERACTIVITY IS ASSOCIATED WITH HYPODOPAMINERGIA IN THE 22- TNJ ENU-MUTATED MOUSE ……………………………….. 354 Published in Alcohol, September 2009 v LIST OF ABBREVIATIONS [DA]p 5-HT: 5-Hydroxytryptamine, Serotonin 5-HT1A, 1A: Serotonin 1A receptor subtype 5-HT1B, 1B: Serotonin 1B receptor subtype 5-HT1B KO: Serrotonin 1B knockout mouse 5-HT1D, 1D: Serotonin 1D receptor subtype 5-HT2A, 2A: Serotonin 2A receptor subtype 5-HT2C, 2C: Serotonin 2C receptor subtype 5-HT6, 6: Serotonin 6 receptor subtype 8-OH-DPAT: R(+)-8-hydroxy-2-(di-n-propylamino)-tetralin ADHD: Attention-deficit/hyperactivity disorder ANOVA: Analysis of variance BCA: Bicinchoninic Acid CGRP: Calcitonin gene-related peptide CNS: Central nervous system CPBG: 1-(m-chlorophenyl)-biguanide CPP: Conditioned place preference CPu: Caudate putamen DA: Dopamine DAp: Dopamine release per stimulus DAT: Dopamine transporter DAT-KO: Dopamine transporter knock-out mouse vi DHBA: 3,4-Dihydroxybenzylamine DOI: 2,5-Dimethoxy-4-iodoamphetamine DRD4: Dopamine D4 receptor subtype DRN: Dorsal raphe nucleus ENU: N-ethyl-N-nitrosourea ERK-2: Extracellular signal-regulated kinase 2 GABA: γ-Aminobutyric acid GBL: Gamma-butyrolactone GR 127, 935: N-[4-methoxy3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5me thyl- 1,2,4-oxadiozol-3-yl)-biphenyl-4-carboxamide GR 55562: 3-(3-dimethylaminopropyl)-4-hydroxy-N-(4-pyridin-4-ylphenyl)- benzamide hydrochloride HPLC: High performance liquid chromatography L-DOPA: L-3,4-dihydroxyphenylalanine mCPP: meta-Chlorophenylpiperazine MDL 100,907: (R)-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol MDMA: 3,4-Methylenedioxymethamphetamine MK 212: agonist 6-chloro-2-(1-piperazinyl)pyrazine HCl MPH: Methylphenidate NAc: Nucleus accumbens NE: Norepinephrine NET: Norepinephrine transporter vii NSD-1015: 3-Hydroxybenzylhydrazine PFC: prefrontal cortex p-MPPF: 4-(2'-methoxy-)-phenyl-1-[2'-(N-2''-pyridinyl)-p-fluorobenzamido-]ethyl- piperazine RU 24969: 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole SR 46349B: 1(Z)-[2-(dimethylamino)ethoxyimino]-1(2-fluorophenyl)-3-(4- hydroxyphenyl)-2(E)-propene SERT: serotonin transporter SSRI: selective serotonin reuptake inhibitor Vmax: rate of transporter uptake VTA: ventral tegmental area WAY 100,635: N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- N-(2- pyridyl)cyclohexanecarboxamide viii LIST OF TABLES AND FIGURES TABLES Page I. The effects of chronic MPH on immediate and long-term neurobiological measures in adolescents………………………………………………….. 12 II. The effects of chronic MPH on immediate and long-term neurobiological measures in adults. ………………………………………………………. 17 III. The effects of chronic MPH on immediate and long-term behavioral measures in adolescents. …………………………………………………. 22 IV. The effects of chronic MPH on immediate and long-term behavioral measures in adults. ……………………………………………………….. 29 V. Effects of chronic MPH on DAT, D2, and SERT levels in the striatum, and on 5-HT1B receptor levels in the ventral midbrain. ………………… 126 FIGURES CHAPTER II Figure 1. Effects of chronic MPH on behavioral and neurochemical responses to cocaine. ……………………………………………………………….. 128 Figure 2. Effects of chronic MPH on behavioral and neurochemical responses to MDMA. ……………………………………………………………….. 131 Figure 3. Effects of chronic MPH on behavioral and neurochemical measures following administration of an SSRI. …………………………………. 134 Figure 4. Effects of chronic MPH on fluoxetine infused into the VTA. ………... 137 ix Figure 5. Effects of chronic MPH on responses to the 5-HT1B agonist RU 141 24969. …………………………………………………………………. CHAPTER III Figure 1. Effects of Chronic MPH on Locomotor Responses to 5-HT receptor agonists. ……………………………………………………………….. 165 Figure 2. Chronic MPH reverses CPP and NAc DA for 5-HT1A agonist 8-OH- DPAT. …………………………………………………………………. 169 Figure 3. Infusion of 8-OH-DPAT into the VTA has differential effects in MPH- treated animals. ………………………………………………………... 172 Figure 4. Chronic MPH reverses CPA and NAc DA for 5-HT1B agonist RU 24969. …………………………………………………………………. 175 Figure 5. Chronic MPH produces sensitization to infusion of 5-HT1B agonist CP93,129 in the VTA. ………………………………………………… 178 Figure 6. Effects of chronic MPH on neurochemical responses to 5-HT1B antagonist GR 55562. …………………………………………………. 181 Figure 7. 5-HT1B antagonists reverse the effects of fluoxetine infusion in MPH- treated animals. ………………………………………………………… 184 CHAPTER IV Figure 1. Effects of chronic MPH on locomotor activity in the open field during habituation and in response to fluoxetine. …………………………… 209 Figure 2. Effects of chronic MPH on Forced Swim Test behavior. ……………... 212 x Figure 3. Effects of chronic MPH on tail suspension test measures. ……………. 215 Figure 4. Effects of chronic
Load more

Recommended publications
  • Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms
    Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms Volume 16, Issue 6 December 2001 EDITORIAL Pebbles of Truth 515 Martin Zatz FEATURE Review Clockless Yeast and the Gears of the Clock: How Do They Mesh? 516 Ruben Baler ARTICLES Resetting of the Circadian Clock by Phytochromes 523 and Cryptochromes in Arabidopsis Marcelo J. Yanovsky, M. Agustina Mazzella, Garry C. Whitelam, and Jorge J. Casal Distinct Pharmacological Mechanisms Leading to c-fos 531 Gene Expression in the Fetal Suprachiasmatic Nucleus Lauren P. Shearman and David R. Weaver Daily Novel Wheel Running Reorganizes and 541 Splits Hamster Circadian Activity Rhythms Michael R. Gorman and Theresa M. Lee Temporal Reorganization of the Suprachiasmatic Nuclei 552 in Hamsters with Split Circadian Rhythms Michael R. Gorman, Steven M. Yellon, and Theresa M. Lee Light-Induced Resetting of the Circadian Pacemaker: 564 Quantitative Analysis of Transient versus Steady-State Phase Shifts Kazuto Watanabe, Tom Deboer, and Johanna H. Meijer Temperature Cycles Induce a Bimodal Activity Pattern in Ruin Lizards: 574 Masking or Clock-Controlled Event? A Seasonal Problem Augusto Foà and Cristiano Bertolucci LETTER Persistence of Masking Responses to Light in Mice Lacking Rods and Cones 585 N. Mrosovsky, Robert J. Lucas, and Russell G. Foster MEETING Eighth Meeting of the Society for Research on Biological Rythms 588 Index 589 Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms EDITOR-IN-CHIEF Martin Zatz FEATURES EDITORS ASSOCIATE EDITORS Larry Morin Michael Hastings SUNY, Stony Brook University of Cambridge Anna Wirz-Justice Ken-Ichi Honma University of Basel Hokkaido Univ School Medicine Michael Young Rockefeller University EDITORIAL BOARD Josephine Arendt Terry Page University of Surrey Vanderbilt University Charles A.
    [Show full text]
  • A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University, [email protected]
    Grand Valley State University ScholarWorks@GVSU Honors Projects Undergraduate Research and Creative Practice 12-2015 Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University, [email protected] Follow this and additional works at: http://scholarworks.gvsu.edu/honorsprojects Part of the Medicine and Health Sciences Commons Recommended Citation Hilla, Devin, "Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment" (2015). Honors Projects. 570. http://scholarworks.gvsu.edu/honorsprojects/570 This Open Access is brought to you for free and open access by the Undergraduate Research and Creative Practice at ScholarWorks@GVSU. It has been accepted for inclusion in Honors Projects by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. Running Head: EFFECTIVE ADHD TREATMENT 1 Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University Honors Senior Thesis EFFECTIVE ADHD TREATMENT 2 Abstract Much debate exists over the proper course of treatment for individuals with attention- deficit/hyperactivity disorder (ADHD). Stimulant medications, such as methylphenidate (e.g., Ritalin) and amphetamine (e.g., Adderall), have been shown to be effective in managing ADHD symptoms. More recently, non-stimulant medications, such as atomoxetine (e.g., Strattera), clonidine (e.g., Kapvay), and guanfacine (e.g., Intuniv), have provided a pharmacological alternative with potentially lesser side effects than stimulants. Behavioral therapies, like behavioral parent training, behavioral classroom management, and behavioral peer interventions, have shown long-term benefits for children with ADHD; however, the success of the short-term management of ADHD symptoms is not as substantial when compared with stimulant medications.
    [Show full text]
  • Gabab Regulation of Methamphetamine-Induced Associative Learning
    Loyola University Chicago Loyola eCommons Dissertations Theses and Dissertations 2010 Gabab Regulation of Methamphetamine-Induced Associative Learning Robin Michelle Voigt Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_diss Part of the Pharmacology Commons Recommended Citation Voigt, Robin Michelle, "Gabab Regulation of Methamphetamine-Induced Associative Learning" (2010). Dissertations. 38. https://ecommons.luc.edu/luc_diss/38 This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 2010 Robin Michelle Voigt LOYOLA UNIVERSITY CHICAGO GABAB REGULATION OF METHAMPHETAMINE-INDUCED ASSOCIATIVE LEARNING A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY PROGRAM IN MOLECULAR PHARMACOLOGY & THERAPEUTICS BY ROBIN MICHELLE VOIGT CHICAGO, IL DECEMBER 2010 Copyright by Robin Michelle Voigt, 2010 All rights reserved ACKNOWLEDGEMENTS Without the support of so many generous and wonderful individuals I would not have been able to be where I am today. First, I would like to thank my Mother for her belief that I could accomplish anything that I set my mind to. I would also like to thank my dissertation advisor, Dr. Celeste Napier, for encouraging and challenging me to be better than I thought possible. I extend gratitude to my committee members, Drs. Julie Kauer, Adriano Marchese, Micky Marinelli, and Karie Scrogin for their guidance and insightful input.
    [Show full text]
  • 1 the ROLE of SERTONIN and VESICULAR MONOAMINE TRANSPORTERS in the ADVERSE RESPONSES to METHYLENEDIOXYMETHAMPHETAMINE by Lucina
    The Role Of Sertonin And Vesicular Monoamine Transporters In The Adverse Responses To Methylenedioxymethamphetamine Item Type text; Electronic Dissertation Authors Lizarraga-Zazueta, Lucina Eridna Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 24/09/2021 17:03:12 Link to Item http://hdl.handle.net/10150/332686 1 THE ROLE OF SERTONIN AND VESICULAR MONOAMINE TRANSPORTERS IN THE ADVERSE RESPONSES TO METHYLENEDIOXYMETHAMPHETAMINE by Lucina Eridna Lizarraga Zazueta A Dissertation Submitted to the Faculty of the DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College at THE UNIVERSITY OF ARIZONA 2014 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Dissertation Committee, we certify that we have read the dissertation prepared by Lucina Eridna Lizarraga Zazueta entitled “The Role of Serotonin and Vesicular Monoamine Transporters in the Adverse Responses to Methylenedioxymethamphetamine” and recommend that it be accepted as fulfilling the dissertation requirement for the Degree of Doctor of Philosophy ________________________________________________________________Date: 06/20/2014 Dr. Terrence J. Monks ________________________________________________________________Date: 06/20/2014 Dr. Serrine S. Lau ________________________________________________________________Date: 06/20/2014 Dr. John W. Regan _______________________________________________________________Date: 06/20/2014 Dr. Josephine Lai ________________________________________________________________Date: 06/20/2014 Dr. Stephen Wright Final approval and acceptance of this dissertation is contingent upon the candidate’s submission of the final copies of the dissertation to the Graduate College.
    [Show full text]
  • Current Research on Methamphetamine-Induced Neurotoxicity: Animal Models of Monoamine Disruption
    J Pharmacol Sci 92, 178 – 195 (2003) Journal of Pharmacological Sciences ©2003 The Japanese Pharmacological Society Critical Review Current Research on Methamphetamine-Induced Neurotoxicity: Animal Models of Monoamine Disruption Taizo Kita1,2, George C. Wagner3, and Toshikatsu Nakashima1,* 1Department of Pharmacology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521 2Department of Pharmacology, Daiichi College of Pharmaceutical Sciences, 22-1 Tamagawacho, Minamiku, Fukuoka 815-8511, Japan 3Department of Psychology, Rutgers, The State University, New Brunswick, NJ 08903, USA Received March 6, 2003 Abstract. Methamphetamine (METH)-induced neurotoxicity is characterized by a long-lasting depletion of striatal dopamine (DA) and serotonin as well as damage to striatal dopaminergic and serotonergic nerve terminals. Several hypotheses regarding the mechanism underlying METH- induced neurotoxicity have been proposed. In particular, it is thought that endogenous DA in the striatum may play an important role in mediating METH-induced neuronal damage. This hypo- thesis is based on the observation of free radical formation and oxidative stress produced by auto- oxidation of DA consequent to its displacement from synaptic vesicles to cytoplasm. In addition, METH-induced neurotoxicity may be linked to the glutamate and nitric oxide systems within the striatum. Moreover, using knockout mice lacking the DA transporter, the vesicular monoamine transporter 2, c-fos, or nitric oxide synthetase, it was determined that these factors may be connected in some way to METH-induced neurotoxicity. Finally a role for apoptosis in METH- induced neurotoxicity has also been established including evidence of protection of bcl-2, expres- sion of p53 protein, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), activity of caspase-3.
    [Show full text]
  • Effects of Ayahuasca on Psychometric Measures of Anxiety, Panic-Like and Hopelessness in Santo Daime Members R.G
    Journal of Ethnopharmacology 112 (2007) 507–513 Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members R.G. Santos a,∗, J. Landeira-Fernandez b, R.J. Strassman c, V. Motta a, A.P.M. Cruz a a Departamento de Processos Psicol´ogicos B´asicos, Instituto de Psicologia, Universidade de Bras´ılia, Asa Norte, Bras´ılia-DF 70910-900, Brazil b Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA c Departamento de Psicologia, Pontif´ıcia Universidade Cat´olica do Rio de Janeiro, PUC-RJ, Brazil Received 21 December 2006; received in revised form 16 April 2007; accepted 18 April 2007 Available online 25 April 2007 Abstract The use of the hallucinogenic brew ayahuasca, obtained from infusing the shredded stalk of the malpighiaceous plant Banisteriopsis caapi with the leaves of other plants such as Psychotria viridis, is growing in urban centers of Europe, South and North America in the last several decades. Despite this diffusion, little is known about its effects on emotional states. The present study investigated the effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in members of the Santo Daime, an ayahuasca-using religion. Standard questionnaires were used to evaluate state-anxiety (STAI-state), trait-anxiety (STAI-trait), panic-like (ASI-R) and hopelessness (BHS) in participants that ingested ayahuasca for at least 10 consecutive years. The study was done in the Santo Daime church, where the questionnaires were administered 1 h after the ingestion of the brew, in a double-blind, placebo-controlled procedure.
    [Show full text]
  • Neuropharmacologic Studies on the Brain Serotonin1a Receptor Using
    December 2013 Biol. Pharm. Bull. 36(12) 1871–1882 (2013) 1871 Review Neuropharmacologic Studies on the Brain Serotonin1A Receptor Using the Selective Agonist Osemozotan Toshio Matsudaa,b a Laboratory of Medicinal Pharmacology, Osaka University Graduate School of Pharmaceutical Sciences; 1–6 Yamada-oka, Suita, Osaka 565–0871, Japan: and b Kanazawa University, Hamamatsu University School of Medicine, Chiba University, University of Fukui, Osaka Univeristy United Graduate School of Child Development; 2–2 Yamada-oka, Suita, Osaka 565–0871, Japan. Received August 13, 2013 Alterations in serotonin (5-HT) neurochemistry have been implicated in the etiology of major neuro- psychiatric disorders such as anxiety-spectrum disorders, depression, and schizophrenia. The neuromodula- tory effects of 5-HT are mediated through 14 receptor subtypes, and those receptors, including the 5-HT1A receptor, are considered to be potential targets for the treatment of psychiatric disorders. We developed the novel 5-HT1A receptor agonist MKC-242 (called osemozotan) and characterized its neurochemical and pharmacological profiles. 5-HT1A receptor agonists modulate the release of amine neurotransmitters through the activation of presynaptic or postsynaptic 5-HT1A receptors in the brain. The agonist has antianxiety and antidepressant effects and improves abnormal behaviors such as aggressive behavior and deficits of prepulse inhibition in isolation-reared mice. We also demonstrated that spinal 5-HT1A receptor activation is involved in isolation rearing-induced hypoalgesia. Concerning the mechanism for induction of isolation-induced ab- normal behaviors, we have recently found that the raphe-prefrontal 5-HT system plays a key role in encoun- ter stimulation-induced hyperactivity in isolation-reared mice. Furthermore, we showed that osemozotan at- tenuates psychostimulant-induced behavioral sensitization and that prefrontal dopamine release is enhanced by functional interaction between the 5-HT1A receptor and other receptors.
    [Show full text]
  • Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review
    Review Article Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review Nadeem Siddiqui, Andalip, Sandhya Bawa, Ruhi Ali, Obaid Afzal, M. Jawaid Akhtar, Bishmillah Azad, Rajiv Kumar Department of ABSTRACT Pharmaceutical Chemistry, Depression is currently the fourth leading cause of disease or disability worldwide. Antidepressant is Faculty of Pharmacy, Jamia Hamdard approved for the treatment of major depression (including paediatric depression), obsessive-compulsive University, Hamdard disorder (in both adult and paediatric populations), bulimia nervosa, panic disorder and premenstrual Nagar, New Delhi - dysphoric disorder. Antidepressant is a psychiatric medication used to alleviate mood disorders, such as 110 062, India major depression and dysthymia and anxiety disorders such as social anxiety disorder. Many drugs produce an antidepressant effect, but restrictions on their use have caused controversy and off-label prescription a Address for correspondence: risk, despite claims of superior efficacy. Our current understanding of its pathogenesis is limited and existing Dr. Sandhya Bawa, E-mail: sandhyabawa761@ treatments are inadequate, providing relief to only a subset of people suffering from depression. Reviews of yahoo.com literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression. Received : 08-02-11 Review completed : 15-02-11 Accepted : 17-02-11 KEY WORDS: Antidepressant, depression, heterocyclic epression is a chronic, recurring and potentially life- monoamine oxidase inhibitors (MAOIs, e.g. Nardil®) tricyclic D threatening illness that affects up to 20% of the population antidepressants (TCAs, e.g. Elavil). They increases the synaptic across the globe.[1] The etiology of the disease is suboptimal concentration of either two (5-HT and NE) or all three (5-HT, concentrations of the monoamine neurotransmitters serotonin NE and dopamine (DA)) neurotransmitters.
    [Show full text]
  • The Dopamine D2, but Not D3 Or D4, Receptor Subtype Is Essential for the Disruption of Prepulse Inhibition Produced by Amphetamine in Mice
    The Journal of Neuroscience, June 1, 1999, 19(11):4627–4633 The Dopamine D2, but not D3 or D4, Receptor Subtype is Essential for the Disruption of Prepulse Inhibition Produced by Amphetamine in Mice Rebecca J. Ralph,1 Geoffrey B. Varty,2 Michele A. Kelly,3 Yan-Min Wang,5 Marc G. Caron,5 Marcelo Rubinstein,6 David K. Grandy,4 Malcolm J. Low,3 and Mark A. Geyer1,2 Departments of 1Neuroscience and 2Psychiatry, University of California at San Diego, La Jolla, California 92093-0804, 3Vollum Institute and 4Department of Physiology and Pharmacology, Oregon Health Sciences University, Portland, Oregon 97201, 5Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham North Carolina 27710, and 6Instituto de Investigaciones en Ingenieria´ Gene´ tica y Biologı´a Molecular, Consejo Nacional de Investigiones Cientı´ficas y Te´ cnicas y Departamento de Biologı´a, Universidad de Buenos Aires, 1428 Buenos Aires, Argentina Brain dopamine (DA) systems are involved in the modulation of observed at baseline. AMPH significantly disrupted PPI in the the sensorimotor gating phenomenon known as prepulse inhi- D2 (1/1) mice but had no effect in the D2 (2/2) mice. After bition (PPI). The class of D2-like receptors, including the D2, AMPH treatment, both DA D3 and D4 receptor (1/1) and (2/2) D3, and D4 receptor subtypes, have all been implicated in the mice had significant disruptions in PPI. These findings indicate control of PPI via studies of DA agonists and antagonists in that the AMPH-induced disruption of PPI is mediated via the rats.
    [Show full text]
  • Rescue of Dopamine Transporter Function in Hypoinsulinemic Rats by a D2 Receptor–ERK-Dependent Mechanism
    The Journal of Neuroscience, February 22, 2012 • 32(8):2637–2647 • 2637 Cellular/Molecular Rescue of Dopamine Transporter Function in Hypoinsulinemic Rats by a D2 Receptor–ERK-Dependent Mechanism W. Anthony Owens,1* Jason M. Williams,3,6,7* Christine Saunders,4,6 Malcolm J. Avison,4,5,7# Aurelio Galli,3,6# and Lynette C. Daws1,2# Departments of 1Physiology and 2Pharmacology, The University of Texas Health Science Center, San Antonio, Texas 78229, and Departments of 3Molecular Physiology and Biophysics, 4Pharmacology, and 5Radiology and Radiological Sciences, 6Center for Molecular Neuroscience, and 7Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee 37232 The dopamine (DA) transporter (DAT) is a major target for abused drugs and a key regulator of extracellular DA. A rapidly growing literature implicates insulin as an important regulator of DAT function. We showed previously that amphetamine (AMPH)-evoked DA release is markedly impaired in rats depleted of insulin with the diabetogenic agent streptozotocin (STZ). Similarly, functional magnetic resonance imaging experiments revealed that the blood oxygenation level-dependent signal following acute AMPH administration in STZ-treated rats is reduced. Here, we report that these deficits are restored by repeated, systemic administration of AMPH (1.78 mg/kg, every other day for 8 d). AMPH stimulates DA D2 receptors indirectly by increasing extracellular DA. Supporting a role for D2 receptors in mediating this “rescue,” the effect was completely blocked by pre-treatment of STZ-treated rats with the D2 receptor antagonist raclopride before systemic AMPH. D2 receptors regulate DAT cell surface expression through ERK1/2 signaling. In ex vivo striatal preparations, repeated AMPH injections increased immunoreactivity of phosphorylated ERK1/2 (p-ERK1/2) in STZ-treated but not control rats.
    [Show full text]
  • Lobelane Analogs with Various Methylene Linker Lengths and Acyclic Lobelane Analogs As Potential Pharmacotherapies to Treat Methamphetamine Abuse
    University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2014 LOBELANE ANALOGS WITH VARIOUS METHYLENE LINKER LENGTHS AND ACYCLIC LOBELANE ANALOGS AS POTENTIAL PHARMACOTHERAPIES TO TREAT METHAMPHETAMINE ABUSE Zheng Cao University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Cao, Zheng, "LOBELANE ANALOGS WITH VARIOUS METHYLENE LINKER LENGTHS AND ACYCLIC LOBELANE ANALOGS AS POTENTIAL PHARMACOTHERAPIES TO TREAT METHAMPHETAMINE ABUSE" (2014). Theses and Dissertations--Pharmacy. 32. https://uknowledge.uky.edu/pharmacy_etds/32 This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]